Tranexamic acid reduces the blood loss and blood transfusion requirements following peri-acetabular osteotomy

Bone Joint J. 2015 Dec;97-B(12):1604-7. doi: 10.1302/0301-620X.97B12.35797.

Abstract

We have investigated the effect of using tranexamic acid (TXA) during peri-acetabular osteotomy (PAO) on peri-operative blood loss and blood transfusion requirements. In addition we analysed whether the use of TXA was associated with an increased risk of venous thromboembolism (VTE) following this procedure. A consecutive series of 96 PAOs, performed by a single surgeon, were reviewed. A total of 48 patients received TXA and 48 did not. The TXA group received a continuous infusion of TXA at a rate of 10 mg/kg/h. The primary outcome measure was the requirement for blood transfusion. Secondary outcomes included total blood loss, the decrease in the level of haemoglobin in the blood, the length of hospital stay, and the complications of this treatment. The mean rate of transfusion was significantly lower in the TXA group (62.5% vs 12.5%, p < 0.001). The mean blood loss was also significantly reduced in the TXA group (1.9 L (standard deviation (SD) 0.9) vs 1.5 L (SD 0.7), p < 0.01). No post-operative episodes of VTE were identified in either group. The use of TXA reduced the blood loss and the rate of transfusion after PAO significantly, without adverse effects such as an increased rate of VTE.

Keywords: Peri-acetabular osteotomy; blood loss; blood transfusion; tranexamic acid.

MeSH terms

  • Acetabulum / surgery*
  • Adolescent
  • Adult
  • Antifibrinolytic Agents / therapeutic use
  • Blood Loss, Surgical / prevention & control*
  • Blood Loss, Surgical / statistics & numerical data
  • Blood Transfusion / trends*
  • Female
  • Follow-Up Studies
  • Hip Dislocation / surgery*
  • Humans
  • Male
  • Middle Aged
  • Osteotomy / adverse effects
  • Osteotomy / methods*
  • Retrospective Studies
  • Tranexamic Acid / therapeutic use*
  • Young Adult

Substances

  • Antifibrinolytic Agents
  • Tranexamic Acid